A molecule made in Russia in the 1990s. Russian studies found memory and mood gains in people whose thinking was already impaired, but no one outside the inventing institute has repeated them, and no study has measured thinking in people who were unimpaired. Raised blood pressure, disrupted sleep and irritability were recorded; product sold outside Russia is frequently mislabeled. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Home blood pressure, seated | 110–125 / 70–80 mmHg | The most consistently reported harm |
| Resting heart rate | 50–70 beats per minute | Detects sympathetic overactivation |
| Montreal Cognitive Assessment | ≥26 of 30, or a rise over the individual's own baseline | Turns a felt effect into a measured one |
| Complete blood count with platelets | Platelets 175–350 × 10⁹/L | Animal data show antiplatelet activity |
| International normalized ratio | 0.9–1.1 untreated; within the prescribed target if anticoagulated | Detects any additive anticoagulant effect |
| Alanine aminotransferase and aspartate aminotransferase | 10–26 U/L for women and 10–33 U/L for men on the first; 10–26 U/L on the second | Liver disease is a manufacturer contraindication |
| Estimated glomerular filtration rate with creatinine | >90 mL/min/1.73 m² | Kidney disease is a manufacturer contraindication |
| Fasting glucose and glycated hemoglobin | Glucose 75–86 mg/dL; glycated hemoglobin 4.8–5.3% | Animal work reports gut-hormone and insulin effects, untested in people |
| Serum brain-derived neurotrophic factor | No established target; track change from the individual's own baseline | The proposed mechanism marker |
Cadence: Baseline before the first dose, including 14 days of home blood-pressure readings; blood pressure and sleep quality weekly throughout the course; cognitive screen repeated at 8 weeks; full blood panel at the end of the course and again at 6 months where courses are repeated.